Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity

Nuclear Medicine and Biology

Volumn 40, Issue 2, 2013, Pages 190-196

  Mebrahtu, Efrem ^a   Zheleznyak, Alexander ^a   Hur, Minjun A ^a   Laforest, Richard ^a   Lapi, Suzanne E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Integrin; MMP; PET; SPECT

Indexed keywords

C(RGDFE)K(DOTA)PLGVRY CU 64; C(RGDFE)K(DOTA)PLGVRY I 123; GELATINASE A; ILOMASTAT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CANCER DIAGNOSIS; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STABILITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SUBSTRATE COMPLEX; FEASIBILITY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; ISOTOPE LABELING; NONHUMAN; PATHOPHYSIOLOGY; PHANTOM; POSITRON EMISSION TOMOGRAPHY; PROTEIN CLEAVAGE; PROTEIN MOTIF; PROTEIN SYNTHESIS; PROTEIN TARGETING; RADIOCHEMISTRY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; COPPER RADIOISOTOPES; DRUG STABILITY; ENZYME ASSAYS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDOLES; INTEGRIN ALPHAVBETA3; IODINE RADIOISOTOPES; ISOTOPE LABELING; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; OLIGOPEPTIDES; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROTEOLYSIS; TIME FACTORS;

EID: 84872922026     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.10.003     Document Type: Article

References (37)

1. Shields A. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 2006, 8:141-150.
2. Van Dort M.E., Rehemtulla A., Ross B.D. PET and SPECT imaging of tumor biology: new approaches towards oncology drug discovery and development. Curr Comput Aided Drug Des 2008, 4:46-53.
3. Carreiras F., Denoux Y., Staedel C., Lehmann M., Sichel F., Gauduchon P. Expression and localization of αv integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996, 62:260-267.
4. Gladson C.L., Hancock S., Arnold M.M., Faye-Petersen O.M., Castleberry R.P., Kelly D.R. Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors. Am J Pathol 1996, 148:1423-1434.
5. Brooks P.C., Strömblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815-1822.
6. Hofmann U.B., Westphal J.R., Waas E.T., Becker J.C., Ruiter D.J., van Muijen G.N.P. Coexpression of integrin [alpha]v[beta]3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol 2000, 115:625-632.
7. Schnell O., Krebs B., Wagner E., Romagna A., Beer A.J., Grau S.J., et al. Expression of integrin αvβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008, 18:378-386.
8. Beer A.J., Haubner R., Goebel M., Luderschmidt S., Spilker M.E., Wester H.-J., et al. Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-Galacto-RGD in cancer patients. J Nucl Med 2005, 46:1333-1341.
9. Beer A., Schwaiger M. Imaging of integrin αvβ3 expression. Cancer Metast Rev 2008, 27:631-644.
10. Edwards W.B., Akers W.J., Ye Y., Cheney P.P., Bloch S., Xu B., et al. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol Imaging 2009, 8:101-110.
11. Chen X., Hou Y., Tohme M., Park R., Khankaldyyan V., Gonzales-Gomez I., et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med 2004, 45:1776-1783.
12. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer I 1997, 89:1260-1270.
13. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999, 284:1667-1670.
14. Ossowski L., Clunie G., Masucci M.T., Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991, 115:1107-1112.
15. Frosch B.A., Berquin I., Emmert-Buck M.R., Moin K., Sloane B.F. Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 1999, 107:28-37.
16. Stearns M.E., Wang M. Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 1993, 53:878-883.
17. Davies B., Waxman J., Wasan H., Abel P., Williams G., Krausz T., et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993, 53:5365-5369.
18. Zucker S., Hymowitz M., Conner C., Zarrabi H.M., Hurewitz A.N., Matrisian L., et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues: clinical and experimental applications. Ann NY Acad Sci 1999, 878:212-227.
19. Moses M.A., Wiederschain D., Loughlin K.R., Zurakowski D., Lamb C.C., Freeman M.R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998, 58:1395-1399.
20. Fang J., Shing Y., Wiederschain D., Yan L., Butterfield C., Jackson G., et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. P Natl Acad Sci USA 2000, 97:3884-3889.
21. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8:221-233.
22. Bremer C., Tung C.-H., Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001, 7:743-748.
23. Bello L., Lucini V., Carrabba G., Giussani C., Machluf M., Pluderi M., et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 2001, 61:8730-8736.
24. McCarthy D.W., Shefer R.E., Klinkowstein R.E., Bass L.A., Margeneau W.H., Cutler C.S., et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997, 24:35-43.
25. Haubner R., Wester H.-J., Reuning U., Senekowitsch-Schmidtke R., Diefenbach B., Kessler H., et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999, 40:1061-1071.
26. Almutairi A., Rossin R., Shokeen M., Hagooly A., Ananth A., Capoccia B., et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. P Natl Acad Sci USA 2009, 106:685-690.
27. Zhang M.-R., Suzuki K. [18F]Fluoroalkyl agents: synthesis, reactivity and application for development of PET ligands in molecular imaging. Curr Top Med Chem 2007, 7:1817-1828.
28. Sellers A., Cartwright E., Murphy G., Reynolds J.J. Evidence that latent collagenases are enzyme-inhibitor complexes. Biochem J 1977, 163:303-307.
29. Galardy R.E., Cassabonne M.E., Giese C., Gilbert J.H., Lapierre F., Lopez H., et al. Low molecular weight inhibitors in corneal ulcerationa. Ann NY Acad Sci 1994, 732:315-323.
30. †. Biochemistry 2008, 47:5986-5995.
31. Goertzen A.L., Bao Q., Bergeron M., Blankemeyer E., Blinder S., Canadas M., et al. NEMA NU 4-2008 comparison of preclinical PET imaging systems. J Nucl Med 2012, 53:1300-1309.
32. Cressman S., Sun Y., Maxwell E.J., Fang N., Chen D.D.Y., Cullis P.R. Binding and uptake of RGD-containing ligands to cellular αvβ3 integrins. Int J Pept Res Ther 2009, 15:49-59.
33. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
34. Ruoslahti E., Pierschbacher M.D. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986, 44:517-518.
35. Pfaff M., Tangemann K., Müller B., Gurrath M., Müller G., Kessler H., et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem 1994, 269:20233-20238.
36. Haubner R., Gratias R., Diefenbach B., Goodman S.L., Jonczyk A., Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αVβ3 antagonists. J Am Chem Soc 1996, 118:7461-7472.
37. Wang W., Wu Q., Pasuelo M., McMurray J.S., Li C. Probing for integrin αvβ3 binding of RGD peptides using fluorescence polarization. Bioconjugate Chem 2005, 16:729-734.